Structure-based design of potent CDK1 inhibitors derived from olomoucine

Journal of Computer-Aided Molecular Design

Volumn 14, Issue 5, 2000, Pages 403-409

  Furet, Pascal ^a   Zimmermann, Juerg ^a   Capraro, Hans Georg ^a   Meyer, Thomas ^a   Imbach, Patricia ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CDK1; Cyclin dependent kinase; Inhibitor; Olomoucine; Structure based design

Indexed keywords

ANTITUMOUR AGENTS; CELL CYCLE; CYCLIN-DEPENDENT KINASE; CYCLIN-DEPENDENT KINASE 1; INHIBITOR; OLOMOUCINE; PURINE DERIVATIVES; STRUCTURE-BASED; STRUCTURE-BASED DESIGNS;

DRUG PRODUCTS;

2 (2 AMINOCYCLOHEXYLAMINO) 6 (3,4 DICHLOROANILINO) 9 ETHYLPURINE; 2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; ADENOSINE TRIPHOSPHATE; ALANINE; ANTINEOPLASTIC AGENT; ASPARTIC ACID; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; GLUTAMIC ACID; GLUTAMINE; GLYCINE; ISOLEUCINE; LEUCINE; LYSINE; NEW DRUG; OLOMOUCINE; PHENYLALANINE; PURINE DERIVATIVE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; MOLECULAR MODEL; PRIORITY JOURNAL;

EID: 0034130669     PISSN: 0920654X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008115004986     Document Type: Article

References (28)

1. Morgan, D.O., Annu. Rev. Cell Dev. Biol., 13 (1997) 261.
2. Nasmyth, K., Science, 274 (1996) 1643.
3. Webster, K.R., Exp. Opin. Invest. Drugs, 7 (1998) 865.
4. Coleman, K.G., Lyssikatos, J.P. and Yang, B.V., Annu. Rep. Med. Chem., 32 (1997) 171.
5. Meijer, L., Trends Cell Biol., 6 (1996) 393.
6. Vesely, J., Havlicek, L., Strnad, M., Blow, J.J., Donella-Deana, A., Pinna, L., Letham, D.S., Kato, J.Y., Detivaud, L., Leclerc, S. and Meijer, L., Eur. J. Biochem., 224 (1994) 771.
7. Imbach, P., Capraro, H.G., Furet, P., Mett, H., Meyer, T. and Zimmermann, J., Bioorg. Med. Chem. Lett., 9 (1999) 91.
8. Hoessel, R., Leclerc, S., Endicott, J.A., Nobel, M.E.M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., Niederberger, E., Tang, W., Eisenbrand, G. and Meijer, L., Nat. Cell Biol., 1 (1999) 60.
9. Lawrie, A.M., Noble, M.E.M., Tunnah, P., Brown, N.R., Johnson, L.N. and Endicott, J.A., Nat. Struct. Biol., 4 (1997) 796.
10. De Azevedo, W.F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M. and Kim, S.H., Eur. J. Biochem., 243 (1997) 518.
11. De Azevedo, W.F., Mueller-Dieckmann, H.J., Schulze-Gahmen, U., Worland, P.J., Sausville, E. and Kim, S.H., Proc. Natl. Acad. Sci. USA, 93 (1996) 2735.
12. Schulze-Gahmen, U., Brandsen, J., Jones, H.D., Morgan, D.O., Meijer, L., Vesely, J. and Kim, S.H., Proteins: Struct. Funct. Genet., 22 (1995) 378.
13. De Bondt, H.L., Rosenblatt, J., Jancarik, J., Jones, H.D., Morgan, D.O. and Kim, S.H., Nature, 363 (1993) 595.
14. Dodin, G., Dreyfus, M. and Dubois, J.E., J. Chem. Soc. Perkin Trans. II, 4 (1979) 438.
15. Hanks, S.K. and Quinn, A.M., Methods Enzymol., 200 (1991) 38.
16. Johnson, L., Lowe, E.D., Noble, M.E.M. and Owen, D.J., FEBS Lett., 430 (1998) 1.
17. Taylor, S.S. and Radzio-Andzelm, E., Structure, 2 (1994) 345.
18. Mohamadi, F., Richards, N.G., Guida, W.C., Liskamp, R., Lipton, M., Caulfield, C., Chang, G., Hendrickson, T. and Still, W.C., J. Comput. Chem., 11 (1990) 440. ('in house' version enhanced for graphies by A. Dietrich - Unpublished results).
19. a. McDonald, D.Q. and Still, W.C., Tetrahedron Lett., 33 (1992) 7743.
20. b. Weiner, S.J., Kollman, P., Case, D.A., Singh, U.C., Ghio, C., Alagona, S., Profeta, S. and Weiner, P., J. Am. Chem. Soc., 106 (1984) 765.
21. Still, W.C., Tempczyk, A., Hawley, R.C. and Hendrickson, T., J. Am. Chem. Soc., 112 (1990) 6127.
22. Zimmermann, J., Buchdunger, E., Fabbro, D., Geiger, Th., Mett, H., Meyer, Th., Muller, M. and Ruetz, S., 215th ACS National Meeting, Dallas, TX, U.S.A., March 29-April 2, 1998.
23. Zimmermann, J., Buchdunger, E., Fabbro, D., Geiger, Th., Mett, H., Meyer, Th., Muller, M. and Ruetz, S., 1st Italian-Swiss Meeting on Medicinal Chemistry, 1997.
24. Other potent inhibitors of CDK1 derived from olomoucine have been reported (References 24-27) since the publication of the patent application covering the compounds described in this paper in 1997 (Zimmermann, J., Capraro, H.G., Peterli, P. and Furet, P., WO 97/716452).
25. Legraverend, M., Ludwig, O., Bisagni, E., Leclerc, S., Meijer, L., Giocanti, N., Sadri, R. and Favaudon V., Bioorg. Med. Chem., 7 (1999) 1281.
26. Chang, Y.T., Gray, N.S., Rosania, G.R., Sutherlin, D.P., Kwon, S., Norman, T.C., Sarohia, R., Leost, M., Meijer, L. and Schultz, P.G., Chem. Biol., 6 (1999) 361.
27. Legraverend, M., Ludwig, O., Bisagni, E., Leclerc, S. and Meijer, L., Bioorg. Med. Chem. Lett., 8 (1998) 793.
28. Havlicek, L., Hanus, J., Vesely, J., Leclerc, S., Meijer, L., Shaw, G. and Strnad, M., J. Med. Chem., 40 (1997) 408.